Table 3

Odds ratios, relative risks and corresponding 95% confidence intervals (CI) for pregabalin and gabapentin versus placebo, and for pregabalin versus gabapentin in the indirect comparison using placebo as the common comparator (sensitivity analyses)

Dose Comparison

Odds Ratio

95% CI

Relative Riska

95% CI


Analysis of Completers


Pregabalin


150 mg vs. Placebo

2.63

1.61, 4.30

2.26

1.52, 3.23

300 mg vs. Placebo

4.23

2.82, 6.36

3.20

2.39, 4.14

600 mg vs. Placebo

6.81

4.50, 10.30

4.31

3.33, 5.34


Gabapentin


900 mg vs. Placebo

2.45

1.44, 4.17

2.14

1.38, 3.17

1200 mg vs. Placebo

2.72

1.72, 4.30

2.32

1.60, 3.23

1800 mg vs. Placebo

3.15

1.64, 6.04

2.59

1.54, 4.02


Pregabalin vs. Gabapentin


150 mg vs. 900 mg

1.07

0.52, 2.21

1.06

0.55, 1.97

300 mg vs. 1200 mg

1.56

0.84, 2.87

1.48

0.85, 2.42

600 mg vs. 1800 mg

2.16

1.00, 4.68b

1.94

1.00, 3.42


Analysis of Responders


Pregabalin


150 mg vs. Placebo

2.85

1.76, 4.63

2.41

1.64, 3.40

300 mg vs. Placebo

3.60

2.41, 5.37

2.86

2.11, 3.74

600 mg vs. Placebo

4.54

3.04, 6.77

3.35

2.52, 4.29


Gabapentin


900 mg vs. Placebo

2.34

1.38, 3.96

2.06

1.33, 3.06

1200 mg vs. Placebo

2.69

1.71, 4.24

2.30

1.60, 3.20

1800 mg vs. Placebo

3.28

1.72, 6.28

2.67

1.60, 4.11


Pregabalin vs. Gabapentin


150 mg vs. 900 mg

1.22

0.60, 2.49

1.19

0.63, 2.17

300 mg vs. 1200 mg

1.34

0.73, 2.45

1.30

0.75, 2.14

600 mg vs. 1800 mg

1.38

0.65, 2.96

1.33

0.67, 2.47


aThese relative-risk values would change with any change in assumption regarding the placebo response rate, currently assumed to be 10%.

bNot significant (rounded up to 1.00).

Delahoy et al. BMC Neurology 2010 10:104   doi:10.1186/1471-2377-10-104

Open Data